atacand 8 mg
astrazeneca ab - suedia - candesartanum cilexetil - compr. - 8mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
atacand 16 mg
astrazeneca ab - suedia - candesartanum cilexetil - compr. - 16mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
atacand 16 mg
astrazeneca ab - suedia - candesartanum cilexetil - compr. - 16mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
atacand 32 mg
astrazeneca ab - suedia - candesartanum cilexetil - compr. - 32mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
atacand 8 mg
astrazeneca ab - suedia - candesartanum cilexetil - compr. - 8mg - antagonisti de angiotensina ii antagonisti de angiotensina ii
polpram 10 mg/10 mg capsule
pharmaceutical works polpharma s.a. - ramiprilum + amlodipinum - capsule - 10 mg/10 mg
polpram 10 mg/5 mg capsule
pharmaceutical works polpharma s.a. - ramiprilum + amlodipinum - capsule - 10 mg/5 mg
polpram 5 mg/10 mg capsule
pharmaceutical works polpharma s.a. - ramiprilum + amlodipinum - capsule - 5 mg/10 mg
polpram 5 mg/5 mg capsule
pharmaceutical works polpharma s.a. - ramiprilum + amlodipinum - capsule - 5 mg/5 mg
nordimet
nordic group b.v. - metotrexat - arthritis, psoriatic; psoriasis; arthritis, juvenile rheumatoid; arthritis, rheumatoid - agenți antineoplazici - nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (jia), when the response to nonsteroidal anti-inflammatory drugs (nsaids) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.